Healthpeak Properties
DOC
$21.40
+0.94%
Healthpeak Properties, Inc. is a real estate investment trust (REIT) that owns and operates a diversified portfolio of approximately 700 healthcare-related properties, primarily consisting of medical office buildings and life science assets, along with senior housing, hospital, and skilled nursing facilities. As a major player in the healthcare REIT sector, Healthpeak distinguishes itself through its scale and focus on high-quality, income-generating properties that cater to the growing demand for healthcare services. The current investor narrative centers on the company's strategic repositioning, as evidenced by a significant stock price surge in May 2026, likely driven by portfolio optimization, strong leasing fundamentals in its lab and medical office segments, and a favorable interest rate environment that supports REIT valuations. Additionally, the company's robust dividend yield and consistent cash flow generation are attracting income-focused investors, while analysts debate the sustainability of its growth trajectory amid evolving healthcare real estate dynamics.…
DOC
Healthpeak Properties
$21.40
Investment Opinion: Should I buy DOC Today?
Based on the analysis, I rate DOC as a Hold. The stock has strong fundamentals, including revenue growth of 7.12% and a high dividend yield of 7.59%, but the valuation is stretched, with a trailing P/E of 160.8x. The analyst consensus is 'Buy' with an average target of $22.87, implying modest upside of 6.9%. However, the negative forward P/E and recent downgrades warrant caution.
Sign up to view all
DOC 12-Month Price Forecast
The AI assessment is neutral, reflecting the balance between positive fundamentals and high valuation. The stock's growth is stable, but the extreme P/E and negative forward P/E raise concerns about sustainability. The high dividend yield provides a floor, but the stock is vulnerable to multiple compression. If the company can deliver consistent earnings growth and the market rewards it, the stock could rise. However, any disappointment could lead to a sharp decline. The stance would upgrade to bullish if the P/E falls below 50x or if revenue growth accelerates above 10%, and downgrade to bearish if the dividend is cut or if earnings turn negative.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Healthpeak Properties's 12-month outlook, with a consensus price target around $22.92 and implied upside of +7.1% versus the current price.
Average Target
$22.92
0 analysts
Implied Upside
+7.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$17 - $29
Analyst target range
Healthpeak is covered by 19 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 2.41 (where 1 is Strong Buy and 5 is Sell). The average target price is $22.87, implying a modest upside of 6.87% from the current price of $21.40. The analyst sentiment is moderately bullish, with a mix of ratings including Outperform and Equal Weight, but no strong buy consensus. The target price range spans from a low of $17.00 to a high of $29.00, indicating a wide dispersion in expectations. The high target of $29.00 suggests that some analysts anticipate significant upside, possibly driven by continued portfolio optimization and strong demand for healthcare properties, while the low target of $17.00 reflects concerns about potential headwinds such as rising interest rates or operational challenges. Recent rating actions show a mix of upgrades and downgrades, with Barclays downgrading from Overweight to Equal Weight in July 2026, and Morgan Stanley downgrading from Overweight to Equal Weight in June 2026, but Mizuho and BMO Capital maintaining Outperform ratings, indicating a cautious but not bearish outlook.
Bulls vs Bears: DOC Investment Factors
Healthpeak presents a mixed picture: strong revenue growth, a high dividend yield, and improving net margins are countered by an extremely high valuation, volatile earnings, and recent analyst downgrades. The bull case rests on the company's ability to sustain growth and improve profitability, while the bear case highlights the risk of valuation compression if earnings disappoint. Currently, the bearish evidence is slightly stronger due to the extreme valuation premium and negative forward P/E, but the company's solid cash flow and strategic positioning in healthcare real estate provide a foundation for potential upside. The key tension is whether the market's high expectations for future earnings growth are justified, as any shortfall could lead to a significant de-rating.
Bullish
- Strong Revenue Growth: Q1 2026 revenue grew 7.12% YoY to $752.95M, with all three segments (Lab, Outpatient Medical, Senior Housing) contributing. This steady growth outpaces the sector average and supports the company's expansion strategy.
- High Dividend Yield: DOC offers a dividend yield of 7.59%, well above the S&P 500 average. The payout ratio of 11.9% indicates the dividend is well-covered by earnings, providing a strong income component for investors.
- Positive Analyst Sentiment: With a consensus 'Buy' rating and an average target price of $22.87, analysts see ~6.9% upside. The high target of $29.00 suggests potential for significant appreciation if the company executes on its strategic plan.
- Improving Net Margin: Net margin improved to 25.72% in Q1 2026 from 15.84% in Q4 2025, indicating better operational efficiency and cost management. This trend, if sustained, could lead to higher earnings and support the stock's valuation.
Bearish
- Extremely High P/E Ratio: The trailing P/E of 160.8x is 543% above the industry average of 25x, indicating the stock is priced for perfection. This leaves little room for error and makes the stock vulnerable to multiple compression if growth disappoints.
- Negative Forward P/E: The forward P/E is -142.67x, implying analysts expect earnings to decline or turn negative. This is a red flag that the market's expectations may be unrealistic, and any earnings miss could trigger a sharp sell-off.
- Volatile Earnings: Net income has swung from a loss of $117.1M in Q3 2025 to a profit of $193.6M in Q1 2026, reflecting the impact of impairments and non-cash items. This volatility makes it difficult to value the company and increases risk for investors.
- Negative Gross Margin: Q1 2026 gross margin was -19.97%, a significant deterioration from positive margins in prior quarters. While partly due to depreciation, it highlights the capital-intensive nature of the business and potential cost pressures.
DOC Technical Analysis
Healthpeak's stock is in a clear uptrend over the past year, with a 23.84% price increase, and the current price of $21.40 sits near the upper end of its 52-week range, at approximately 93% of the high of $22.95 and 36% above the low of $15.70. This positioning near the highs indicates strong momentum and investor confidence, though it also raises the risk of a short-term pullback as the stock may be overextended. The 1-year relative strength versus the S&P 500 is positive at 3.36%, suggesting the stock has outperformed the broader market.
Beta
1.00
1.00x market volatility
Max Drawdown
-18.5%
Largest decline past year
52-Week Range
$16-$23
Price range past year
Annual Return
+23.8%
Cumulative gain past year
| Period | DOC Return | S&P 500 |
|---|---|---|
| 1m | -3.6% | +3.6% |
| 3m | +8.5% | +2.7% |
| 6m | +26.0% | +11.4% |
| 1y | +23.8% | +18.7% |
| ytd | +32.1% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DOC Fundamental Analysis
Healthpeak's revenue has been growing steadily, with the most recent quarter (Q1 2026) reporting revenue of $752.95 million, a 7.12% year-over-year increase, and the company has consistently posted revenue above $700 million for the past several quarters, indicating a stable growth trajectory. The revenue growth is driven by all three segments: Lab ($212.8M), Outpatient Medical Buildings ($318.2M), and Senior Housing ($200.3M), with the outpatient medical buildings segment being the largest contributor. The company's profitability has been volatile, with net income swinging from a loss of $117.1 million in Q3 2025 to a profit of $193.6 million in Q1 2026, reflecting the impact of non-cash items and impairments; however, the gross margin turned negative in Q1 2026 at -19.97%, which is a red flag, though this is largely due to depreciation and amortization costs typical of REITs. The net margin improved to 25.72% in Q1 2026, up from 15.84% in Q4 2025, indicating better operational efficiency. Healthpeak maintains a healthy balance sheet with a debt-to-equity ratio of 1.39, which is moderate for a REIT, and it generated $236.9 million in free cash flow in Q1 2026, providing ample coverage for its dividend payments of $211.99 million in the same period.
Quarterly Revenue
$752952000.0B
2026-03
Revenue YoY Growth
+7.1%
YoY Comparison
Gross Margin
-20.0%
Latest Quarter
Free Cash Flow
$1.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DOC Overvalued?
Given that Healthpeak has positive net income, we use the trailing P/E ratio as the primary valuation metric. The trailing P/E stands at 160.8x, which is extremely high, while the forward P/E is negative at -142.67x, indicating that analysts expect earnings to decline or become negative in the near term, which is unusual and suggests the market is pricing in significant growth or a recovery in earnings. Compared to the industry average P/E of 25x (based on historical data), Healthpeak trades at a substantial premium of 543%, which is not justified by its growth metrics, as its revenue growth is only 7.12% and its net margin is 2.53% (trailing). The stock's P/S ratio of 3.97x is also higher than the sector average of 2.5x, indicating a premium valuation. Historically, Healthpeak's P/E has ranged from as low as 8.68x in Q3 2022 to over 800x in Q4 2024, and the current 160.8x is near the higher end of its historical range, suggesting that the market has high expectations for future earnings growth, which may be optimistic given the company's recent earnings volatility.
PE
160.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 9x~96x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are significant. The company's debt-to-equity ratio of 1.39 is moderate for a REIT, but the high interest expense of $87.3M in Q1 2026 could pressure earnings if rates rise. The negative gross margin of -19.97% in Q1 2026, though partly due to depreciation, indicates potential cost issues. Earnings volatility is a major concern, with net income swinging from a loss of $117.1M in Q3 2025 to a profit of $193.6M in Q1 2026, making it difficult to predict future performance. The payout ratio of 11.9% is low, but the dividend yield of 7.59% is high, and if cash flow declines, the dividend could be at risk.